74788-82-2

Usage

Uses

Used in Pharmaceutical Industry:
2,6-Dimethylbenzylamine is used as an intermediate in the synthesis of flavin derivatives for therapeutic use as anti-infective agents. These flavin derivatives have potential applications in the development of new drugs to combat infections caused by bacteria, viruses, and other pathogens.

InChI:InChI=1/C9H13N/c1-7-4-3-5-8(2)9(7)6-10/h3-5H,6,10H2,1-2H3

Upstream product

• 6575-13-9 2,6-dimethylbenzonitrile 
• 130403-21-3 2-(2,6-di-methylbenzyl)isoindoline-1,3-dione 
• 632-46-2 2,6-dimethylbenzoic acid 
• 5402-60-8 2,6-dimethylbenzyl chloride 

Downstream Products

• 54521-25-4 (2,6-dimethyl-benzyl)-dimethyl-amine 
• 157840-51-2 N⁶-(2,6-Dimethyl-benzyl)-3-nitro-pyridine-2,6-diamine 
• 1027226-32-9 4-(2,6-dimethyl-benzylcarbamoyl)-thiazolidine-3-carboxylic acid tert-butyl ester 
• 1094462-37-9 N-(2,6-dimethylphenylmethyl)-1H-benzofuro[3,2-c]pyrazol-3-amine 
• 1050479-68-9 C₁₅H₁₅FN₂O₂ 
• 1352818-98-4 N-(2,6-dimethylbenzyl)picolinamide 

Relevant academic research and scientific papers

Compounds for the treatment of metabolic disorders

Compounds useful for the treatment of various metabolic disorders, such as insulin resistance syndrome, diabetes, hyperlipidemia, fatty liver disease, cachexia, obesity, atherosclerosis and arteriosclerosis, are disclosed.

Benzimidazole Derivatives

Novel compounds of the formula I (I), in which R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, R12, R13, R, Q, W,

Compounds for the treatment of metabolic disorders

Compounds useful for the treatment of various metabolic disorders, such as insulin resistance syndrome, diabetes, hyperlipidemia, fatty liver disease, cachexia, obesity, atherosclerosis and arteriosclerosis, are disclosed.

Structure-activity relationship of small-sized HIV protease inhibitors containing allophenylnorstatine

We designed and synthesized a new class of peptidomimetic human immunodeficiency virus (HIV) protease inhibitors containing a unique unnatural amino acid, allophenylnorstatine [Apns; (2S,3S)-3-amino-2-hydroxy- 4-phenylbutyric acid], with a hydroxymethylcarbonyl (HMC) isostere as the active moiety. A systematic evaluation of structure - activity relationships for HIV protease inhibition, anti-HIV activities, and pharmacokinetic profiles has led to the delineation of a set of structural characteristics that appear to afford an orally available HIV protease inhibitor. Optimum structures, exemplified by 21f (JE-2147), incorporated 3-hydroxy-2- methylbenzoyl groups as the P2 ligand, (R)-5,5-dimethyl-1,3-thiazolidine-4- carbonyl (Dmt) residue at the P1' site, and 2-methylbenzylcarboxamide group as the P2' ligand. The present study demonstrated that JE-2147 has potent antiviral activities in vitro and exhibits good oral bioavailability and plasma pharmacokinetic profiles in two species of laboratory animals.

Novel isoxazole and isoxazoline compounds with anticonvulsant activity process for their preparation and therapeutic composition containing them

The object of the invention are anticonvulsant heterocyclic compounds of general formula: STR1 in which R1 and R2 is each selected from C1 -C4 alkyl, phenyl, benzyl, trifluoromethyl or halogen, R3 is